Q2 EPS Forecast for CRISPR Therapeutics Reduced by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at William Blair cut their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a research note issued on Wednesday, May 7th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($1.10) per share for the quarter, down from their prior estimate of ($1.01). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($3.16) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the previous year, the business posted ($1.43) earnings per share. The firm's revenue for the quarter was up 71.6% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on CRSP. Chardan Capital decreased their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Friday, March 21st. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Finally, Citigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded down $1.55 on Friday, hitting $35.67. The stock had a trading volume of 1,909,050 shares, compared to its average volume of 1,670,483. The stock's 50 day moving average is $38.03 and its 200-day moving average is $42.64. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -8.16 and a beta of 1.88. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This represents a 12.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last three months. Corporate insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently modified their holdings of CRSP. Northwestern Mutual Wealth Management Co. raised its position in shares of CRISPR Therapeutics by 75.2% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 6,873 shares of the company's stock valued at $234,000 after buying an additional 2,949 shares during the last quarter. Quantbot Technologies LP lifted its position in shares of CRISPR Therapeutics by 272.4% in the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock worth $45,000 after acquiring an additional 978 shares during the period. Raymond James Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 5.6% during the 1st quarter. Raymond James Financial Inc. now owns 86,666 shares of the company's stock worth $2,949,000 after purchasing an additional 4,571 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of CRISPR Therapeutics by 49,248.8% during the first quarter. EverSource Wealth Advisors LLC now owns 84,880 shares of the company's stock valued at $2,888,000 after purchasing an additional 84,708 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of CRISPR Therapeutics in the first quarter valued at $629,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.